Year-end Sale % OFF 
Abstract
The 2023 Precision Oncology Summit was organized by Binaytara foundation in San Francisco on October 7th and 8th. The theme of the conference was to discuss the recent advances in precision oncology and future directions to move away from a one-size-fits-all model in order to improve patient outcomes. This manuscript reviews the session on precision oncology in solid tumors. The first lecture during this session was on tumor-agnostic FDA approvals delivered by Peter J. O’Dwyer, M.D., whereas the second lecture by Pauline Funchain, M.D., discussed melanoma as a paradigm for precision immuno-oncology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
